Summary by Moomoo AI
On April 1, 2024, Cingulate Inc., a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, and provided updates on its clinical and business operations. The company reported raising $17.8 million since the beginning of 2023 and converting $9.1 million of debt into equity at a premium. Cingulate's lead ADHD treatment, CTx-1301, continued to show promising results in Phase 3 trials. The company also discussed the potential for non-dilutive capital and expansion of its asset pipeline. Cingulate has raised additional funds in 2024, including $10.7 million from the sale of securities and $3.3 million of debt conversion to equity by Werth Family Investment Associates, LLC. Jennifer Callahan was promoted to CFO, and three independent directors were appointed to the board. As of December 31, 2023, Cingulate had...Show More